Press Releases Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 20:00:00 09/03/2026 GMT			5-day change	1st Jan Change
146.63 ^USD	+1.88%		-2.27%	+19.46%

03-09	IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, Potential PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update	CI
03-09	Global drugmakers rush to boost US presence as tariff threat looms	RE

Press Releases

03-09	Bringing It Home - South Africa is Leading the Charge to Make Anti-HIV jab for Africa	AQ
03-02	Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia	BU
02-25	Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy	BU
02-24	Gilead Sciences : to-Present-at-Upcoming-Investor-Conferences	PU
02-23	Gilead Sciences to Present at Upcoming Investor Conferences	BU
02-23	Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel	BU
02-22	A long-acting HIV drug arrives in Zimbabwe for some at highest risk	AQ
02-17	Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options	BU
02-11	Gilead Sciences : Q4 2025 Earnings Presentation	PU
02-10	Gilead Sciences : Fourth Quarter 2025 Resource Book	PU
02-10	Gilead Sciences : Fourth Quarter 2025 Prepared Remarks	PU
02-10	Gilead Sciences : Fourth Quarter 2025 Summary of Remarks	PU
02-10	Gilead Sciences : Fourth Quarter 2025 Supplementary Information	PU
02-10	Gilead: Q4 Earnings Snapshot	AQ
02-10	Gilead Sciences Announces 3.8 Percent Increase in First Quarter 2026 Dividend	BU
02-10	Gilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results	BU
02-06	FDA Approves Label Update for Kite’s Yescarta® for Relapsed/Refractory Primary Central Nervous System Lymphoma	BU
01-27	Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026	BU
01-21	New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer	BU
01-10	Gilead Sciences : Fourth Quarter 2025 Estimated Acquired IPR&D	PU
12-22	Gilead Sciences to Present at Upcoming Investor Conference	BU
12-22	Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes	BU
12-22	Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans	AQ
12-19	Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans	BU
12-18	Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance	BU